4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics, Inc. (FDMT) is named in a Form 144 notice for a proposed sale by its officer, David Kirn, of 114,746 Class A Common shares. The notice lists an approximate sale date of June 22, 2026, and an aggregate market value of $1,195,653.32.
The notice also lists a June 1, 2026 sale of 1,922 shares for gross proceeds of $19,257.86. Goldman Sachs & Co. LLC is named as broker. The proposed sale is connected with a selling plan dated January 9, 2026, intended to comply with Rule 10b5-1(c).
4D Molecular Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the record date on April 20, 2026, there were 52,274,735 common shares outstanding, and 44,038,022 shares were represented in person or by proxy at the meeting.
Stockholders elected Class III directors Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello, MBA to serve until the 2029 Annual Meeting or until their successors are elected. Votes for these nominees ranged from 30.5 million to 35.9 million, with additional broker non-votes recorded.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 43,900,362 votes for. In an advisory vote, stockholders approved the compensation of named executive officers, with 36,065,437 votes for and 940,414 against.
4D Molecular Therapeutics director Shawn Tomasello received a new stock option grant as part of non-employee director compensation. The award covers options to buy 50,000 shares of common stock at an exercise price of $9.42 per share, expiring on June 16, 2036.
One-third of the option vests on June 17, 2027, with the remaining shares vesting in equal monthly installments until fully vested on June 17, 2029, provided she continues serving the company. The option will vest in full if a Change in Control occurs under the company’s 2020 Incentive Award Plan.
4D Molecular Therapeutics director Charles Theuer received a grant of stock options for 50,000 shares of common stock as part of non-employee director compensation. The options have an exercise price of $9.42 per share and expire on June 16, 2036.
One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until full vesting on June 17, 2029, contingent on continued service. The options also vest in full if a Change in Control, as defined in the 2020 Incentive Award Plan, is completed.
4D Molecular Therapeutics director Nancy Miller-Rich received a new stock option grant for 50,000 shares of common stock. The options have an exercise price of $9.42 per share and were granted at no cost as part of the company’s non-employee director compensation program.
The option vests over time: one-third of the shares vest on June 17, 2027, with the remaining shares vesting in equal monthly installments until fully vested on June 17, 2029, assuming continued service. The options will also vest in full if a Change in Control occurs under the 2020 Incentive Award Plan.
4D Molecular Therapeutics director Susannah Gray received a grant of stock options for 50,000 shares of common stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036. One-third of the options vest on June 17, 2027, with the remainder vesting in equal monthly installments until fully vested on June 17, 2029, as long as she continues serving the company. The options were automatically granted under the non-employee director compensation program, and this grant brings her direct option holdings reported in this filing to 50,000 shares.
4D Molecular Therapeutics director John F. Milligan received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $9.42 per share and were automatically granted under the non-employee director compensation program. One-third vests on June 17, 2027, with the rest vesting in equal monthly installments until fully vested on June 17, 2029, or sooner upon a Change in Control, and they expire on June 16, 2036.
4D Molecular Therapeutics director Glenn Sblendorio received a grant of stock options for 50,000 shares of Common Stock. The options have an exercise price of $9.42 per share and expire on June 16, 2036, and are held directly.
The grant was automatically made under the company’s non-employee director compensation program. One-third of the options vest on June 17, 2027, with the remaining shares vesting in equal monthly installments until full vesting on June 17, 2029, or earlier upon a Change in Control under the 2020 Incentive Award Plan. Following this award, Sblendorio holds options for 50,000 shares from this grant.
4D Molecular Therapeutics director Jacob Chacko received a new stock option grant covering 50,000 shares of common stock. The option has an exercise price of $9.42 per share and expires on June 16, 2036. It was granted automatically under the company’s non-employee director compensation program.
The option vests as to one-third of the shares on June 17, 2027, then in equal monthly installments until fully vested on June 17, 2029, contingent on his continued service. The award will also vest in full upon a Change in Control as defined in the 2020 Incentive Award Plan. Following this grant, he holds options for 50,000 shares directly.
4D Molecular Therapeutics director and officer David Kirn reported an open‑market sale of 1,922 shares of Common Stock at a weighted average price of $10.0197 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026 and was carried out in multiple trades between $10.00 and $10.055 per share.
Following this sale, Kirn directly holds 1,057,231 shares of the company’s common stock, indicating he retained a substantial position after the transaction.